Q1 Company News Roundup with Wall Street Analyst Kyle Mikson

What kind of market share can Illumina expect when it launches its own MRD kits and is it worth the risk of annoying customers that also offer those tests? Why did liquid biopsy company stocks do so well in May?What were his headline takeaways from the recent American Society of Clinical Oncology annual meeting?Where is he going on summer vacation after a hectic several months?Tune in to hear the answers to these questions, and more.If you’re interested in learning more about Kyle’s takes on the life science tools and diagnostics industries, you can reach out to him on LinkedIn to start a conversation. https://www.linkedin.com/in/kylemiksoncfa/For full disclosure, he asked me to note that Seer is an investment banking client of Canaccord Genuity.